SCHEMBL6097459

SCHEMBL6097459

O=[N+]([O-])c1c(O)c2ccccc2n2nnnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S100A4 P26447 2/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
ALDH1A1 P00352 5/20 0.38
MAPT P10636 5/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
RAB9A P51151 3/20 0.36
NPC1 O15118 3/20 0.36
LMNA P02545 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL6101423 0.99 S100A4 (0.46) S100A4MEN1KMT2AGRIN2DGRIN3B
Water SCHEMBL8467556 0.89 MEN1 (0.38) S100A4MEN1KMT2AGRIN2DGRIN3B
SCHEMBL6106397 0.83 ALDH1A1 (0.51) S100A4MEN1KMT2AALDH1A1MAPT
SCHEMBL6099876 0.83 LMNA (0.40) S100A4MEN1KMT2AALDH1A1MAPT
SCHEMBL6100932 0.82 S100A4 (0.34) S100A4MEN1KMT2AGRIN2DGRIN3B
SCHEMBL6100934 0.82 S100A4 (0.34) S100A4MEN1KMT2AGRIN2DGRIN3B
SCHEMBL3354370 0.81 S100A4 (0.42) S100A4MEN1KMT2AGRIN2DGRIN3B
SCHEMBL842306 0.81 MAPT (0.42) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL6100506 0.80 MAPT (0.47) MEN1KMT2AALDH1A1MAPTSMN1; SMN2
SCHEMBL6099481 0.78 ALDH1A1 (0.40) MEN1KMT2AALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0912565-B1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES MINNESOTA MINING & MFG (US) 2004-04-14 EP claimed
US-20040019213-A1 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-29 US claimed
US-6613902-B2 Induce biosynthesis of cytokines such as interferons, interleukins, and tumor necrosis factor in humans and in mice. 3M INNOVATIVE PROPERTIES COMPANY 2003-09-02 US claimed
US-20030153762-A1 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY 2003-08-14 US claimed
US-20030130516-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES 3M INNOVATIVE PROPERTIES COMPANY 2003-07-10 US claimed
US-20020188127-A1 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY 2002-12-12 US claimed
EP-0912565-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-05-06 EP claimed
US-5741908-A Process for reparing imidazoquinolinamines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-04-21 US claimed
WO-1997048704-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-12-24 WO claimed
US-20080161573-A1 PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF DIPHARMA S.P.A. (IT) 2008-07-03 US disclosed
US-7301027-B2 Process for the preparation of Imiquimod and intermediates thereof DIPHARMA S.P.A. (IT) 2007-11-27 US disclosed
US-7301027-B2 Process for the preparation of Imiquimod and intermediates thereof DIPHARMA S.P.A. (IT) 2007-11-27 US disclosed
US-7026482-B2 Process for preparing imidazoquinolinamines MEDICIS PHARMACEUTICAL CORPORATION 2006-04-11 US disclosed
US-6989389-B2 Aryl ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES CO. (US) 2006-01-24 US disclosed
EP-0912565-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-05-06 EP disclosed
EP-0912564-A1 PROCESS FOR PREPARING TETRAHYDROIMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-05-06 EP disclosed
US-5741908-A Process for reparing imidazoquinolinamines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-04-21 US disclosed
WO-1997048704-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-12-24 WO disclosed
WO-1997048703-A1 PROCESS FOR PREPARING TETRAHYDROIMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-12-24 WO disclosed
US-5693811-A Process for preparing tetrahdroimidazoquinolinamines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161573-A1 PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF MYD88, TLR7, MAVS S100A4 2595/4885MEN1 3676/4885KMT2A 1184/4885
US-20040019213-A1 Process for preparing imidazoquinolinamines VAT1, QARS1, TALDO1 S100A4 2670/4885MEN1 1398/4885KMT2A 542/4885
US-20020188127-A1 Process for preparing imidazoquinolinamines VAT1, QARS1, TALDO1 S100A4 2670/4885MEN1 1398/4885KMT2A 542/4885
US-20030130516-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES VAT1, QARS1, TALDO1 S100A4 2670/4885MEN1 1398/4885KMT2A 542/4885
US-20030153762-A1 Process for preparing imidazoquinolinamines VAT1, QARS1, TALDO1 S100A4 2670/4885MEN1 1398/4885KMT2A 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.